Neurocognition in bipolar disorders-A closer look at comorbidities and medications

European Journal of Pharmacology

Volumn 626, Issue 1, 2010, Pages 87-96

  Balanzá Martínez, Vicent ^a   Selva, Gabriel ^a   Martínez Arán, Anabel ^b   Prickaerts, Jos ^c   Salazar, José ^a   González Pinto, Ana ^d   Vieta, Eduard ^b   Tabarés Seisdedos, Rafael ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Anticonvulsant; Antipsychotic; Bipolar disorder; Comorbidity; Iatrogenic effect; Lithium; Neuropsychology

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; GABAPENTIN ENACARBIL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALZHEIMER DISEASE; ANTEROGRADE AMNESIA; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG USE; EPILEPSY; HUMAN; LEARNING DISORDER; LOW DRUG DOSE; MAJOR DEPRESSION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOMOTOR DISORDER; PSYCHOMOTOR RETARDATION; PSYCHOPHARMACOTHERAPY; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; VERBAL COMMUNICATION;

ANIMALS; BIPOLAR DISORDER; COGNITION DISORDERS; COMORBIDITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 70849120352     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.018     Document Type: Review

References (132)

1. Altshuler L.L., Ventura J., van Gorp W.G., Green M.F., Theberge D.C., and Mintz J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol. Psychiatry 56 (2004) 560-569
2. Amado-Boccara I., Gougoulis N., Littre M.F.P., Galinowski A., and Loo H. Effects of antidepressants on cognitive functions: a review. Neurosci. Biobehav. Rev. 19 (1995) 479-493
3. Ananth J., Ghadirian A.M., and Engelsmann F. Lithium and memory: a review. Can. J. Psychiatry 32 (1987) 312-316
4. Andreasen N.C. Creativity and mental illness: prevalence rates in writers and their first-degree relatives. Am. J. Psychiatry 144 (1987) 1288-1292
5. Angst J., Gamma A., Gerber-Werder R., Zarate C.A., and Manji H.K. Does long-term medication with lithium, clozapine or antidepressants prevent or attenuate dementia in bipolar and depressed patients?. Int. J. Psychiatry Clin. Pract. 11 (2007) 2-8
6. Arts B., Jabben N., Krabbendam L., and van Os J. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol. Med. 38 (2008) 771-785
7. Balanzá-Martínez V., Tabarés-Seisdedos R., Selva-Vera G., Martínez-Arán A., Torrent C., Salazar-Fraile J., Leal-Cercós C., Vieta E., and Gómez-Beneyto M. Persistent cognitive dysfunctions in bipolar-I and schizophrenic patients: a 3-year follow-up study. Psychother. Psychosom. 74 (2005) 113-119
8. Balanzá-Martínez V., Rubio C., Selva-Vera G., Martinez-Aran A., Sánchez-Moreno J., Salazar-Fraile J., Vieta E., and Tabarés-Seisdedos R. Neurocognitive endophenotypes (endophenocognitypes) from studies of relatives of bipolar disorder subjects: a systematic review. Neurosci. Biobehav. Rev. 32 (2008) 1426-1438
9. Basso M.R., Lowery N., Neel J., Purdie R., and Bornstein R.A. Neuropsychological impairment among manic, depressed, and mixed-episode in patients with bipolar disorder. Neuropsychology 16 (2002) 84-91
10. Bauer M., Alda M., Priller J., Young L.T., and International Group For The Study Of Lithium Treated Patients (IGSLI. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36 Suppl 3 (2003) S250-S254
11. Bearden C.E., Glahn D.C., Caetano S., Olvera R.L., Fonseca M., Najt P., Hunter K., Pliszka S.R., and Soares J.C. Evidence for disruption in prefrontal cortical functions in juvenile bipolar disorder. Bipolar Disord. 9 Suppl 1 (2007) 145-159
12. Bearden C.E., Thompson P.M., Dalwani M., Hayashi K.M., Lee A.D., Nicoletti M., Trakhtenbroit M., Glahn D.C., Brambilla P., Sassi R.B., Mallinger A.G., Frank E., Kupfer D.J., and Soares J.C. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol. Psychiatry 62 (2007) 7-16
13. Block R.I., Erwin W.J., and Ghoneim M.M. Chronic drug use and cognitive impairments. Pharmacol. Biochem. Behav. 73 (2002) 491-504
14. Bonnín, C.M., Martínez-Arán, A., Torrent, C., Pacchiarotti, I., Rosa, A.R., Franco, C., Murru, A., Sanchez-Moreno, J., Vieta, E., in press. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J. Affect. Disord. doi:10.1016/j.jad.2009.05.014
15. Bora E., Vahip S., Akdeniz F., Gonul A.S., Eryavuz A., Ogut M., and Alkan M. The effect of previous psychotic mood episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord. 9 (2007) 468-477
16. Bora E., Yucel M., and Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J. Affect. Disord. 113 (2009) 1-20
17. Brambilla P., Glahn D.C., Balestrieri M., and Soares J.C. Magnetic resonance findings in bipolar disorder. Psychiatr. Clin. North. Am. 28 (2005) 443-467
18. Brissos S., Dias V.V., Carita A.I., and Martinez-Arán A. Quality of life in bipolar type I disorder and schizophrenia in remission: clinical and neurocognitive correlates. Psychiatry Res. 160 (2008) 55-62
19. Brooks J.O., and Hoblyn J.C. Neurocognitive costs and benefits of psychotropic medications in older adults. J. Geriatr. Psychiatry Neurol. 20 (2007) 199-214
20. Brunbech L., and Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy-a comparative review of newer versus older agents. Drugs 62 (2002) 593-604
21. Buffett-Jerrott S.E., and Stewart S.H. Cognitive and sedative effects of benzodiazepine use. Curr. Pharm. Des. 8 (2002) 45-58
22. Burdick K.E., Goldberg J.F., Harrow M., Faull R.N., and Malhotra A.K. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J. Nerv. Ment. Dis. 194 (2006) 255-260
23. Burdick K.E., Funke B., Goldberg J.F., Bates J.A., Jaeger J., Kucherlapati R., and Malhotra A.K. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord. 9 (2007) 370-376
24. Burdick K.E., Braga R.J., Goldberg J.F., and Malhotra A.K. Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs 21 (2007) 971-981
25. Cahill C.M., Malhi G.S., Ivanovski B., Lagopoulos J., and Cohen M. Cognitive compromise in bipolar disorder with chronic cannabis use: cause or consequence?. Expert Rev. Neurother. 6 (2006) 591-598
26. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., and Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75 (2000) 1729-1734
27. Chen P.S., Peng G.S., Li G., Yang S., Wu X., Wang C.C., Wilson B., Lu R.B., Gean P.W., Chuang D.M., and Hong J.S. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006) 1116-1125
28. Clark L., Iversen S.D., and Goodwin G.M. Sustained attention deficit in bipolar disorder. Br. J. Psychiatry 180 (2002) 313-319
29. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32 (2006) 9-16
30. Daban C., Martínez-Arán A., Torrent C., Sánchez-Moreno J., Goikolea J.M., Benabarre A., Comes M., Colom F., and Vieta E. Cognitive functioning in bipolar patients receiving lamotrigine: preliminary results. J. Clin. Psychopharmacol. 26 (2006) 178-181
31. Depp C.A., Savla G.N., Moore D.J., Palmer B.W., Stricker J.L., Lebowitz B.D., and Jeste D.V. Short-term course of neuropsychological abilities in middle-aged and older adults with bipolar disorder. Bipolar Disord. 10 (2008) 684-690
32. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Cole S., Krivogorsky B., and Yolken R.H. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol. Psychiatry 55 (2004) 588-593
33. Dickerson F.B., Boronow J.J., Stallings C., Origoni A.E., Cole S., Leister F., Krivogorsky B., and Yolken R.H. The catechol O-methyltransferase Val158Met polymorphism and herpes simplex virus type 1 infection are risk factors for cognitive impairment in bipolar disorder: additive gene-environmental effects in a complex human psychiatric disorder. Bipolar Disord. 8 (2006) 124-132
34. Dickstein D.P., Treland J.E., Snow J., McClure E.B., Mehta M.S., Towbin K.E., Pine D.S., and Leibenluft E. Neuropsychological performance in pediatric bipolar disorder. Biol. Psychiatry 55 (2004) 32-39
35. Donaldson S., Goldstein L.H., Landau S., Raymont V., and Frangou S. The Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. J. Clin. Psychiatry 64 (2003) 86-93
36. El-Badri S.M., Ashton C.H., Moore P.B., Marsh V.R., and Ferrier I.N. Electrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disord. 3 (2001) 79-87
37. Engelsmann F., Katz J., Ghadirian A.M., and Schachter D. Lithium and memory: a long-term follow-up study. J. Clin. Psychopharmacol. 8 (1988) 207-212
38. Ferrier I.N., and Thompson J.M. Cognitive impairment in bipolar affective disorder: implications for the bipolar diathesis. Br. J. Psychiatry 180 (2002) 293-295
39. Fountoulakis K.N., Vieta E., Bouras C., Notaridis G., Giannakopoulos P., Kaprinis G., and Akiskal H. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?. Int. J. Neuropsychopharmacol. 11 (2008) 269-287
40. Frangou S., Donaldson S., Hadjulis M., Landau S., and Goldstein L.H. The Maudsley Bipolar Disorder Project: executive dysfunction in bipolar disorder I and its clinical correlates. Biol. Psychiatry 58 (2005) 859-864
41. Glahn D.C., Bearden C.E., Niendam T.A., and Escamilla M.A. The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disord. 6 (2004) 171-182
42. Glahn D.C., Bearden C.E., Barguil M., Barrett J., Reichenberg A., Bowden C.L., Soares J.C., and Velligan D.I. The neurocognitive signature of psychotic bipolar disorder. Biol. Psychiatry 62 (2007) 910-916
43. Goldberg J.F., and Burdick K.E. Cognitive side effects of anticonvulsants. J. Clin. Psychiatry 62 Suppl 14 (2001) 27-33
44. Goodwin F.K., and Jamison K.R. Manic Depressive Illness: Bipolar Disorders and Recurrent Depression. second ed. (2007), Oxford University Press, New York, NY
45. Goodwin G.M., Martinez-Aran A., Glahn D.C., and Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur. Neuropsychopharmacol. 18 (2008) 787-793
46. Grant I., Gonzalez R., Carey C.L., Natarajan L., and Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J. Int. Neuropsychol. Soc. 9 (2003) 679-689
47. Gualtieri C.T., and Johnson L.G. Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. Med. Gen. Med. 8 (2006) 46
48. Harvey P.D., Hassman H., Mao L., Gharabawi G.M., Mahmoud R.A., and Engelhart L.M. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J. Clin. Psychiatry 68 (2007) 1186-1194
49. Holmes M.K., Erickson K., Luckenbaugh D.A., Drevets W.C., Bain E.E., Cannon D.M., Snow J., Sahakian B.J., Manji H.K., and Zarate Jr. C.A. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord. 10 (2008) 806-815
50. Honig A., Arts B.M., Ponds R.W., and Riedel W.J. Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. Int. Clin. Psychopharmacol. 14 (1999) 167-171
51. Jaeger J., Berns S., Loftus S., Gonzalez C., and Czobor P. Neurocognitive test performance predicts functional recovery from acute exacerbation leading to hospitalization in bipolar disorder. Bipolar Disord. 9 (2007) 93-102
52. Jamrozinski K., Gruber O., Kemmer C., Falkai P., and Scherk H. Neurocognitive functions in euthymic bipolar patients. Acta Psychiatr. Scand. 119 (2009) 365-374
53. Joseph M.F., Frazier T.W., Youngstrom E.A., and Soares J.C. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol. 18 (2008) 595-605
54. Kaye N.S., Graham J., Roberts J., Thompson T., and Nanry K. Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder. J. Clin. Psychopharmacol. 27 (2007) 387-391
55. Kessing L.V., Søndergård L., Forman J.L., and Andersen P.K. Lithium treatment and risk of dementia. Arch. Gen. Psychiatry 65 (2008) 1331-1335
56. Khan A., Ginsberg L.D., Asnis G.M., Goodwin F.K., Davis K.H., Krishnan A.A., and Adams B.E. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J. Clin. Psychiatry 65 (2004) 1483-1490
57. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8455-8459
58. Kocsis J.H., Shaw E.D., Stokes P.E., Wilner P., Elliot A.S., Sikes C., Myers B., Manevitz A., and Parides M. Neuropsychologic effects of lithium discontinuation. J. Clin. Psychopharmacol. 13 (1993) 268-275
59. Kowatch R.A., Youngstrom E.A., Danielyan A., and Findling R.L. Review and meta-analysis of the phenomenology and clinical characteristics of mania in children and adolescents. Bipolar Disord. 7 (2005) 483-496
60. Krishnan K.R. Psychiatric and medical comorbidities of bipolar disorder. Psychosom. Med. 67 (2005) 1-8
61. Lagace D.C., and Eisch A.J. Mood-stabilizing drugs: are their neuroprotective aspects clinically relevant?. Psychiatr. Clin. North. Am. 28 (2005) 399-414
62. Lahera G., Montes J.M., Benito A., Valdivia M., Medina E., Mirapeix I., and Sáiz-Ruiz J. Theory of mind deficit in bipolar disorder: is it related to a previous history of psychotic symptoms?. Psychiatry Res. 161 (2008) 309-317
63. Law C.W., Soczynska J.K., Woldeyohannes H.O., Miranda A., Brooks III J.O., and McIntyre R.S. Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. Pharmacol. Biochem. Behav. 92 (2009) 12-16
64. Levy B., Monzani B.A., Stephansky M.R., and Weiss R.D. Neurocognitive impairment in patients with co-occurring bipolar disorder and alcohol dependence upon discharge from inpatient care. Psychiatry Res. 161 (2008) 28-35
65. Loring D.W., Marino S., and Meador K.J. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol. Rev. 17 (2007) 413-425
66. MacQueen G., and Young T. Cognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders. Bipolar Disord. 5 Suppl. 2 (2003) 53-61
67. Malhi G.S., Ivanovski B., Hadzi-Pavlovic D., Mitchell P.B., Vieta E., and Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord. 9 (2007) 114-125
68. Manji H.K., and Duman R.S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull. 35 (2001) 5-49
69. Martin R., Kuzniecky R., Ho S., Hetherington H., Pan J., Sinclair K., Gilliam F., and Faught E. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52 (1999) 321-327
70. Martinez-Aran A., Vieta E., Reinares M., Colom F., Torrent C., Sanchez-Moreno J., Benabarre A., Goikolea J., Comes M., and Salamero M. Cognitive function across manic or hypomanic, depressed and euthymic states in bipolar disorder. Am. J. Psychiatry 161 (2004) 262-270
71. Martinez-Aran A., Vieta E., Torrent C., Sanchez-Moreno J., Goikolea J.M., Salamero M., Malhi G.S., Gonzalez-Pinto A., Daban C., Alvarez-Grandi S., Fountoulakis K., Kaprinis G., Tabares-Seisdedos R., and Ayuso-Mateos J.L. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 9 (2007) 103-113
72. Martinez-Arán A., Torrent C., Tabares-Seisdedos R., Salamero M., Daban C., Balanza- Martinez V., Sanchez-Moreno J., Goikolea J.M., Benabarre A., Colom F., and Vieta E. Neurocognitive impairment in bipolar patients with and without history of psychosis. J. Clin. Psychiatry 69 (2008) 233-239
73. Martínez-Arán A., Vieta E., Colom F., Reinares M., Benabarre A., Torrent C., Goikolea J.M., Corbella B., Sánchez-Moreno J., and Salamero M. Neuropsychological performance in depressed and euthymic bipolar patients. Neuropsychobiology 46 Suppl 1 (2002) 16-21
74. Martínez-Arán A., Vieta E., Colom F., Torrent C., Reinares M., Goikolea J.M., Benabarre A., Comes M., and Sánchez-Moreno J. Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment?. Psychother. Psychosom. 74 (2005) 295-302
75. Martino D.J., Strejilevich S.A., Scápola M., Igoa A., Marengo E., Ais E.D., and Perinot L. Heterogeneity in cognitive functioning among patients with bipolar disorder. J. Affect. Disord. 109 (2008) 149-156
76. Martino D.J., Marengo E., Igoa A., Scápola M., Ais E.D., Perinot L., and Strejilevich S.A. Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J. Affect. Disord 116 (2009) 37-42
77. McClure E.B., Treland J.E., Snow J., Dickstein D.P., Towbin K.E., Charney D.S., Pine D.S., and Leibenluft E. Memory and learning in pediatric bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry 44 (2005) 461-469
78. McIntyre R.S., Soczynska J.K., Beyer J.L., Woldeyohannes H.O., Law C.W., Miranda A., Konarski J.Z., and Kennedy S.H. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr. Opin. Psychiatry 20 (2007) 406-416
79. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., Kalayjian L.A., Kanner A., Liporace J.D., Pennell P.B., Privitera M., Loring D.W., and Group N. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360 (2009) 1597-1605
80. Moore G.J., Bebchuk J.M., Wilds I.B., Chen G., and Manji H.K. Lithium-induced increase in human brain grey matter. Lancet 356 (2000) 1241-1242
81. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., Faulk M.W., Koch S., Glitz D.A., Jolkovsky L., and Manji H.K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?. Biol. Psychiatry 48 (2000) 1-8
82. Moore G.J., Cortese B.M., Glitz D.A., Zajac-Benitez C., Quiroz J.A., Uhde T.W., Drevets W.C., and Manji H.K. A longitudinal study of the effects of lithium treatment on prefrontal and subgenual prefrontal gray matter volume in treatment-responsive bipolar disorder patients. J. Clin. Psychiatry 70 (2009) 699-705
83. Moorhead T.W., McKirdy J., Sussmann J.E., Hall J., Lawrie S.M., Johnstone E.C., and McIntosh A.M. Progressive gray matter loss in patients with bipolar disorder. Biol. Psychiatry 62 (2007) 894-900
84. Mula M., Trimble M.R., Thompson P., and Sander J.W. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60 (2003) 1104-1107
85. Mur M., Portella M.J., Martínez-Arán A., Pifarré J., and Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J. Clin. Psychiatry 69 (2008) 712-719
86. Mur M., Portella M.J., Martínez-Arán A., Pifarré J., and Vieta E. Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic bipolar patients evaluated at a 2-year interval. Acta Psychiatr. Scand. 118 (2008) 373-381
87. Murphy F.C., and Sahakian B.J. Neuropsychology of bipolar disorder. Br. J. Psychiatry 178 Supl 4 (2001) 120-127
88. Nunes P.V., Forlenza O.V., and Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar Disorder. Br. J. Psychiatry 190 (2007) 359-360
89. Ortinski P., and Meador K.J. Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 5 Suppl 1 (2004) S60-S65
90. Pachet A.K., and Wisniewski A.M. The effects of lithium on cognition: an updated review. Psychopharmacology 170 (2003) 225-234
91. Paterniti S., Dufouil C., and Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J. Clin. Psychopharmacol. 22 (2002) 285-293
92. Pavuluri M.N., Schenkel L.S., Aryal S., Harral E.M., Hill S.K., Herbener E.S., and Sweeney J.A. Neurocognitive function in unmedicated manic and medicated euthymic pediatric bipolar patients. Am. J. Psychiatry 163 (2006) 286-293
93. Pavuluri M.N., West A., Hill S.K., Jindal K., and Sweeney J.A. Neurocognitive function in pediatric bipolar disorder: 3-year follow-up shows cognitive development lagging behind healthy youths. J. Am. Acad. Child Adolesc. Psychiatry 48 (2009) 299-307
94. Quraishi S., and Frangou S. Neuropsychology of bipolar disorders: a review. J. Affect. Disord 72 (2002) 209-226
95. Reinares M., Martinez-Aran A., Colom F., Benabarre A., Salamero M., and Vieta E. Efectos a largo plazo del tratamiento con risperidona versus neurolépticos convencionales en el rendimiento neuropsicológico de pacientes bipolares eutímicos. Actas Esp. Psiquiatr. 28 (2000) 231-238
96. Robinson L.J., and Ferrier I.N. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 8 (2006) 103-116
97. Robinson L.J., Thompson J.M., Gallagher P., Goswami U., Young A.H., Ferrier I.N., and Moore P.B. A meta analysis of cognitive deficits in euthymic patients with bipolar disorder. J. Affect. Disord. 93 (2006) 105-115
98. Rybakowski J.K., Borkowska A., Skibinska M., Szczepankiewicz A., Kapelski P., Leszczynska-Rodziewicz A., Czerski P.M., and Hauser J. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene. Psychiatry Clin. Neurosci. 60 (2006) 70-76
99. Sanchez-Moreno, J., Martinez-Aran, A., Colom, F., Scott, J., Tabares-Seisdedos, R., Sugranyes, G., Torrent, C., Daban, C., Benabarre, A., Goikolea, J.M., Franco, C., Gonzalez-Pinto, A., Ayuso-Mateos, J.L., Vieta, E., 2009. Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. J. Clin. Psychiatry. 70, 1120-1127.
100. Sánchez-Morla E.M., Barabash A., Martínez-Vizcaíno V., Tabarés-Seisdedos R., Balanzá-Martínez V., Cabranes-Díaz J.A., Baca-Baldomero E., and Santos Gómez J.L. Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients. Psychiatry Res. 169 (2009) 220-228
101. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., and Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301 (2003) 805-809
102. Sassi R.B., Nicoletti M., Brambilla P., Mallinger A.G., Frank E., Kupfer D.J., Keshavan M.S., and Soares J.C. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci. Lett. 329 (2002) 243-245
103. Savitz J.B., Solms M., and Ramesar R.S. Neurocognitive function as an endophenotype for genetic studies of bipolar affective disorder. Neuromolecular Med. 7 (2005) 275-286
104. Savitz J.B., van der Merwe L., Stein D.J., Solms M., and Ramesar R.S. Neuropsychological task performance in bipolar spectrum illness: genetics, alcohol abuse, medication and childhood trauma. Bipolar Disord. 10 (2008) 479-494
105. Sbrana A., Bizzari J.V., Rucci P., Gonelli C., Doria M.R., Spagnolli S., Ravani L., Raimondi F., Dell'Osso L., and Cassano G.B. The spectrum of substance use in mood andanxiety disorders. Compr. Psychiatry 46 (2005) 6-13
106. Schloesser R.J., Huang J., Klein P.S., and Manji H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33 (2008) 110-133
107. Selva G., Salazar J., Balanzá-Martínez V., Martinez-Arán A., Rubio C., Daban C., Sánchez- Moreno J., Vieta E., and Tabarés-Seisdedos R. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?. J. Psychiatr. Res. 41 (2007) 265-272
108. Senturk V., Goker C., Bilgic A., Olmez S., Tugcu H., Oncu B., and Atbasoglu E.C. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord. 9 Suppl 1 (2007) 136-144
109. Sheline Y.I., Gado M.H., and Kraemer H.C. Untreated depression and hippocampal volume loss. Am. J. Psychiatry 160 (2003) 1516-1518
110. Simonsen C., Sundet K., Vaskinn A., Birkenaes A.B., Engh J.A., Hansen C.F., Jónsdóttir H., Ringen P.A., Opjpordsmoen S., Fris S., and Andreassen O.E. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord. 10 (2008) 245-255
111. Stip E., Dufresne J., Lussier I., and Yatham L. A double-blind, placebo-controlled study of the effects of lithium on cognition in healthy subjects: mild and selective effects on learning. J. Affect. Disord. 60 (2000) 147-157
112. Szöke A., Meary A., Trandafir A., Bellivier F., Roy I., Schurhoff F., and Leboyer M. Executive deficits in psychotic and bipolar disorders-implications for our understanding of schizoaffective disorder. Eur. Psychiatry 23 (2008) 20-25
113. Tabarés-Seisdedos R., Balanzá-Martínez V., Salazar-Fraile J., Selva-Vera G., Leal-Cercós C., and Gómez-Beneyto M. Specific executive/attentional deficits in patients with schizophrenia or bipolar disorder who have a positive family history of psychosis. J. Psychol. Res. 37 (2003) 479-486
114. Tabarés-Seisdedos R., Escámez T., Martínez-Giménez J.A., Balanzá V., Salazar J., Selva G., Rubio C., Vieta E., Geijó-Barrientos E., Martínez-Arán A., Reiner O., and Martínez S. Variations in genes regulating neuronal migration predict reduced prefrontal cognition in schizophrenia and bipolar subjects from Mediterranean Spain: a preliminary study. Neuroscience 139 (2006) 1289-1300
115. Tabarés-Seisdedos R., Balanzá-Martínez V., Sánchez-Moreno J., Martinez-Aran A., Salazar- Fraile J., Selva-Vera G., Rubio C., Mata I., Gómez-Beneyto M., and Vieta E. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 109 (2008) 286-299
116. Tabarés-Seisdedos R., Mata I., Escámez T., Vieta E., López-Ilundain J.M., Salazar J., Selva G., Balanzá V., Rubio C., Martínez-Arán A., Valdés-Sánchez L., Geijo-Barrientos E., and Martínez S. Evidence for association between structural variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish isolate population. Psychiatr. Genet. 18 (2008) 313-317
117. Taylor Tavares J.V., Clark L., Cannon D.M., Erickson K., Drevets W.C., and Sahakian B.J. Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Biol. Psychiatry 62 (2007) 917-924
118. Terao T., Nakano H., Inoue Y., Okamoto T., Nakamura J., and Iwata N. Lithium and dementia: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1125-1128
119. Thompson J.M., Gallagher P., Hughes J.H., Watson S., Gray J.M., Ferrier I.N., and Young A.H. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br. J. Psychiatry 186 (2005) 32-40
120. Torrent C., Martinez-Aran A., Daban C., Sanchez-Moreno J., Comes M., Goikolea J.M., Salamero M., and Vieta E. Cognitive impairment in bipolar II disorder. Br. J. Psychiatry 189 (2006) 254-259
121. Torrent, C., Martinez-Arán, A., Daban, C., Amann, B., Balanzá-Martínez, V., Bonnín, C.M., Tabarés-Seisdedos, R., Vieta, E., in press. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.
122. Torres I.J., Boudreau V.G., and Yatham L.N. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr. Scand. Suppl. 434 (2007) 17-26
123. Tsai S.Y., Lee H.C., Chen C.C., and Huang Y.L. Cognitive impairment in later life in patients with early-onset bipolar disorder. Bipolar Disord. 9 (2007) 868-875
124. Tsaltas E., Kontis D., Boulougouris V., and Papadimitriou G.N. Lithium and cognitive enhancement: leave it or take it?. Psychopharmacology (Berl) 202 (2009) 457-476
125. van der Schot A.C., Vonk R., Brans R.G., van Haren N.E., Koolschijn P.C., Nuboer V., Schnack H.G., van Baal G.C., Boomsma D.I., Nolen W.A., Hulshoff Pol H.E., and Kahn R.S. Influence of genes and environment on brain volumes in twin pairs concordant and discordant for bipolar disorder. Arch. Gen. Psychiatry 66 (2009) 142-151
126. Van Gorp W.G., Altshuler L., Theberge D.C., Wilkins J., and Dickson W. Cognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. Arch. Gen. Psychiatry 55 (1998) 41-46
127. Wingo A.P., Harvey P.D., and Baldessarini R.J. Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord. 11 (2009) 113-125
128. Young R.C., Murphy C.F., Heo M., Schulberg H.C., and Alexopoulos G.S. Cognitive impairment in bipolar disorder in old age: literature review and findings in manic patients. J. Affect. Disord. 92 (2006) 125-131
129. Yu H., Zhang Z., Shi Y., Bai F., Xie C., Qian Y., Yuan Y., and Deng L. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. J. Clin. Psychiatry 69 (2008) 1104-1111
130. Yucel K., McKinnon M.C., Taylor V.H., Macdonald K., Alda M., Young L.T., and MacQueen G.M. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl) 195 (2007) 357-367
131. Zobel A.W., Schulze-Rauschenbach S., von Widdern O.C., Metten M., Freymann N., Grasmäder K., Pfeiffer U., Schnell S., Wagner M., and Maier W. Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment. J. Psychiatr. Res. 38 (2004) 377-383
132. Zubieta J.K., Huguelet P., O'Neil R.L., and Giordani B.J. Cognitive function in euthymic bipolar I disorder. Psychiatry Res. 102 (2001) 9-20